Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis.
Adv TherJun 12, 2026 (epub)
Andrew J Cutler, Anaïs Lemyre, Qiaoyi Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated the efficacy and safety of lumateperone compared to other atypical antipsychotics in adults with major depressive disorder (MDD). The analysis included 10 randomized clinical trials. Lumateperone 42 mg/day showed the highest mean difference from placebo in Montgomery-Åsberg Depression Rating Scale scores at -4.70, indicating superior efficacy.
Key findings
- Lumateperone 42 mg/day had the highest mean difference from placebo in MADRS scores at -4.70.
- Lumateperone ranked first for weight-related safety outcomes, showing no weight gain.
- Active treatments were favored over placebo in 10 out of 11 efficacy endpoints.
- Lumateperone ranked better than average for akathisia risk but below average for somnolence risk.
Why it matters
The findings highlight the potential of lumateperone as an effective adjunctive treatment for MDD, particularly for patients who do not respond adequately to antidepressants alone. Its favorable safety profile, especially regarding weight gain, is significant for long-term management.